Cellular Resistance Against Troxacitabine in Human Cell Lines and Pediatric Patient Acute Myeloid Leukemia Blast Cells

Autor:	Isabelle Hubeek, G.J. Peters, A.D. Adema, Gertjan L. Kaspers, Linda Zuurbier, K. Floor, F. Albertoni
Přispěvatelé:	Pathology, Hematology laboratory, Pediatric surgery, Internal medicine
Rok vydání:	2006
Předmět:	Troxacitabine Antineoplastic Agents HL-60 Cells Deoxycytidine Biochemistry Catalysis Cytosine Inhibitory Concentration 50 chemistry.chemical_compound Cell Line Tumor Genetics medicine Humans Cladribine Myeloid leukemia Dioxolanes Nucleosides General Medicine Deoxycytidine kinase medicine.disease Gemcitabine Leukemia Myeloid Acute Leukemia Models Chemical chemistry Drug Resistance Neoplasm Cancer research Molecular Medicine Nucleoside HeLa Cells medicine.drug
Zdroj:	Nucleosides, Nucleotides and Nucleic Acids, 25(9-11), 981-986. Taylor and Francis Ltd. Adema, A D, Zuurbier, L, Floor, K, Hubeek, I, Kaspers, G J L, Albertoni, F & Peters, G J 2006, ' Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells ', Nucleosides, Nucleotides and Nucleic Acids, vol. 25, no. 9-11, pp. 981-986 . https://doi.org/10.1080/15257770600889212
ISSN:	1532-2335 1525-7770
Popis:	Troxacitabine is a cytotoxic deoxycytidine analogue with an unnatural L-configuration, which is activated by deoxycytidine kinase (dCK). The configuration is responsible for differences in the uptake and metabolism of troxacitabine compared to other deoxynucleoside analogues. To determine whether troxacitabine has an advantage over other nucleoside analogues several cell lines resistant to cladribine and gemcitabine were exposed to troxacitabine, while blast cells from pediatric leukemia patients were tested for cross-resistance with other deoxynucleoside analogues. The gemcitabine resistant AG6000 (IC50: > 3000 nM), and the cladribine resistant CEM (IC50: 150 nM) and HL-60 (IC50: > 3000 nM) cell lines, all with no or decreased dCK expression, were less sensitive to troxacitabine than their wild type counterparts (IC50; A2780: 410, CEM: 71 and HL-60: 158 nM). dCK protein expression in CEM was higher than in HL-60, which, in turn, was higher than in A2780. Catalytically inactive p53 seems to increase the sensitivity to troxacitabine. The patient samples showed a large range of sensitivity to troxacitabine, similar to other deoxynucleoside analogues. Cross-resistance with all other deoxynucleoside analogues was observed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a1073aaba8d5cddba67fe20fbc53ec https://doi.org/10.1080/15257770600889212 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.